Momelotinib Dihydrochloride Patent Expiration

Momelotinib Dihydrochloride is used for treating intermediate or high-risk myelofibrosis. It was first introduced by Glaxosmithkline Llc in its drug Ojjaara on Sep 15, 2023.

Momelotinib Dihydrochloride Patents

Given below is the list of patents protecting Momelotinib Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ojjaara US8486941 Phenyl amino pyrimidine compounds and uses thereof Jan 03, 2030 Glaxosmithkline
Ojjaara US9809559 (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Jun 11, 2035 Glaxosmithkline
Ojjaara USRE48285 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Jun 11, 2035 Glaxosmithkline

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳